Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M

Enanta Pharmaceuticals reports 2018 executive compensation

Enanta Pharmaceuticals reported fiscal year 2018 executive compensation information on January 18, 2019.

In 2018, five executives at Enanta Pharmaceuticals received on average a compensation package of $2.1M, a 5% decrease compared to previous year.

Average pay of disclosed executives at Enanta Pharmaceuticals

Jay R. Luly, Chief Executive Officer, received $4.5M in total, which increased by 5% compared to 2017. 59.54% of Luly's compensation, or $2.7M, was in option awards. Luly also received $355.7K in non-equity incentive plan, $611.2K in salary, $838.5K in stock awards, as well as $18.9K in other compensation.

Yat Sun Or, Chief Scientific Officer, received a compensation package of $1.5M, which decreased by 14% compared to previous year. 41.39% of the compensation package, or $630.9K, was in option awards.

Nathalie Adda, Chief Medical Officer, earned $1.5M in 2018, a 14% decrease compared to previous year.

Paul J. Mellett, Chief Financial Officer, received $1.4M in 2018, which decreases by 11% compared to 2017.

Nathaniel S. Gardiner, General Counsel, earned $1.4M in 2018, a 9% decrease compared to previous year.

Enanta Pharmaceuticals' fiscal year ends on September 30.